Prospective Evaluation of Intravitreal Triamcinolone Acetonide Injection in Macular Edema Associated with Retinal Vascular Disorders
- 1 September 2005
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 15 (5) , 619-626
- https://doi.org/10.1177/112067210501500513
Abstract
Purpose: To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity and macular thickness using optical coherence tomography (OCT) in macular edema associated with various retinal vascular disorders. Methods: This prospective nonrandomized clinical interventional study included 81 eyes (76 patients) comprised of Group I, 57 eyes (51 patients) with diabetic macular edema; Group II, 10 eyes (10 patients) with branch retinal vein occlusion; and Group III, 13 eyes (13 patients) with central retinal vein occlusion. All eyes received an intravitreal injection of 4 mg triamcinolone acetonide (with the solvent) in the operation theater under sterile conditions. Results: Mean preinjection central macular thickness was 531.84±132 μm in Group I, 458.4±149 μm in Group II, and 750.81±148 μm in Group III. All groups showed a statistically significant decrease in mean central macular thickness at 1 month (300.7±119 μM in Group I, 218.2±99 μm in Group II, and 210.5 ±56 μm in Group III) and 3 months (253.19±109 μm in Group I, 187±47 μm in Group II, and 182±50 μm in Group III) after injection (p<0.05). Mean follow-up was 22±2.4 weeks. Mean visual acuity increased in all three groups (preoperative visual acuity in Group I, 1.2±0.4 logMAR units; Group II, 1.24±0.5 logMAR units; Group III, 1.1 ±0.4 logMAR units; 1 month postinjection in Group I, 0.88±0.3 logMAR units; Group II, 0.67±0.3 logMAR units; Group III, 0.86±0.4 logMAR units; 3 months postinjection in Group I, 0.84±0.4 logMAR units; Group II, 0.59±0.3 logMAR units; Group III, 0.82±0.5 logMAR units) (p 24 mmHg). One eye developed infective endophthalmitis. Conclusions: Intravitreal injection of triamcinolone acetonide may be considered as an effective treatment for reducing macular thickening due to diffuse diabetic macular edema, venous occlusion associated macular edema, and may result in increase in visual acuity at least in the short term. Further follow-up and analysis is required to demonstrate its long-term efficacy.Keywords
This publication has 34 references indexed in Scilit:
- Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edemaAmerican Journal of Ophthalmology, 2004
- Branch retinal vein occlusion treated by intravitreal triamcinolone acetonideEye, 2004
- Intravitreal triamcinolone acetonide for diabetic diffuse macular edema11The authors have no proprietary interest in this study. 22Dr Audren, co–first author, contributed equally to the work.Ophthalmology, 2004
- Morphological and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusionActa Ophthalmologica Scandinavica, 2003
- Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injectionOphthalmology, 2003
- INTRAVITREAL TRIAMCINOLONE ACETONIDE IN EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2000
- Intravitreal triamcinolone and elevated intraocular pressureAustralian and New Zealand Journal of Ophthalmology, 1999
- Natural History and Clinical Management of Central Retinal Vein OcclusionArchives of Ophthalmology (1950), 1997
- Modified Grid Laser Photocoagulation for Diffuse Diabetic Macular EdemaOphthalmology, 1991
- Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema.British Journal of Ophthalmology, 1984